PMID- 20066450
OWN - NLM
STAT- MEDLINE
DCOM- 20100527
LR  - 20220409
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 29
IP  - 4
DP  - 2010 Apr
TI  - Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab 
      in psoriatic arthritis patients who experienced an inadequate response to 
      previous disease-modifying antirheumatic drugs.
PG  - 399-403
LID - 10.1007/s10067-009-1340-7 [doi]
AB  - The aim of this study is to compare effectiveness and safety of Infliximab (INF), 
      Etanercept (ETN), and Adalimumab (ADA) in patients with psoriatic arthritis (PsA) 
      with inadequate response to a previous disease-modifying antirheumatic drug 
      (DMARD). One hundred consecutive PsA patients with inadequate response to a 
      previous DMARD entered this study. Clinical and laboratory assessment at baseline 
      (T0) and 12 (T12) months were performed and included physical examination, vital 
      signs, global Psoriasis Area and Severity Index (PASI; extension of psoriasis), 
      tender joints count (TJC), swollen joint count, health assessment questionnaire 
      (HAQ; questionnaire for measuring disability), and monitoring of adverse events 
      (AEs). After enrollment, all patients were randomly given INF 5 mg/Kg every 6-8 
      weeks, ETN 50 mg weekly, or ADA 40 mg every other week. Baseline therapy with 
      DMARD remained unchanged. Effectiveness was defined as percentage of ACR20 
      responders and as clinical remission and/or minimal disease activity at 12 months 
      treatment. INF, ETN, and ADA all effectively controlled signs and symptoms of 
      PsA. All variables tested showed at T12 for each treatment a significant 
      variation from the baseline value. In particular, patients on INF and ADA showed 
      the greatest improvement in terms of PASI, while patients on ETN showed the 
      greatest improvement on TJC and HAQ. ACR response rates were 72% of patients on 
      ETN, 70% of those on ADA, and 75% of those patients on INF. Occurrence of AEs was 
      reported in 15% of the cases. Only two AEs in patients on INF were considered 
      drug related, pneumonitis and thrombocytopenia, respectively. All tumor necrosis 
      factor-alpha blockers significantly controlled signs and symptoms of PsA. An 
      increased knowledge of the different profiles of these agents may help in 
      optimizing their use.
FAU - Atteno, Mariangela
AU  - Atteno M
AD  - Department of Clinical and Experimental Medicine, Early Psoriatic Arthritis 
      Clinic, University Federico II, Naples, Italy.
FAU - Peluso, Rosario
AU  - Peluso R
FAU - Costa, Luisa
AU  - Costa L
FAU - Padula, Stefania
AU  - Padula S
FAU - Iervolino, Salvatore
AU  - Iervolino S
FAU - Caso, Francesco
AU  - Caso F
FAU - Sanduzzi, Alessandro
AU  - Sanduzzi A
FAU - Lubrano, Ennio
AU  - Lubrano E
FAU - Del Puente, Antonio
AU  - Del Puente A
FAU - Scarpa, Raffaele
AU  - Scarpa R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/pharmacology/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/pharmacology/*therapeutic use
MH  - Infliximab
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2010/01/13 06:00
MHDA- 2010/05/28 06:00
CRDT- 2010/01/13 06:00
PHST- 2009/06/16 00:00 [received]
PHST- 2009/12/08 00:00 [accepted]
PHST- 2009/11/30 00:00 [revised]
PHST- 2010/01/13 06:00 [entrez]
PHST- 2010/01/13 06:00 [pubmed]
PHST- 2010/05/28 06:00 [medline]
AID - 10.1007/s10067-009-1340-7 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2010 Apr;29(4):399-403. doi: 10.1007/s10067-009-1340-7.